ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
70.67
2.18
(3.18%)
Closed June 22 4:00PM
70.60
-0.07
(-0.10%)
After Hours: 7:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
61.008.2510.204.509.2250.000.00 %00-
62.007.359.004.108.1750.000.00 %05-
63.006.008.657.427.3251.6729.04 %5596/21/2024
64.004.958.007.856.4753.8495.76 %32296/21/2024
65.005.156.856.706.003.0081.08 %467366/21/2024
66.004.354.954.964.652.1174.04 %1767616/21/2024
67.001.854.003.652.9251.5573.81 %5601,6726/21/2024
68.002.422.972.922.6951.4598.64 %8558986/21/2024
69.001.912.202.502.0551.52155.10 %3078216/21/2024
70.001.401.451.471.4250.80119.40 %9927546/21/2024
71.000.910.960.920.9350.46100.00 %1,7364886/21/2024
72.000.560.600.610.580.33117.86 %4,0341,3866/21/2024
73.000.330.400.400.3650.22122.22 %3,3581336/21/2024
74.000.200.260.220.230.0857.14 %1,578726/21/2024
75.000.130.170.190.150.0872.73 %1,0169746/21/2024
76.000.060.120.060.09-0.02-25.00 %4088036/21/2024
77.000.050.230.080.14-0.01-11.11 %25146/21/2024
78.000.030.070.060.05-0.02-25.00 %167406/21/2024
79.000.010.110.130.060.000.00 %31206/21/2024
80.000.030.050.050.04-0.03-37.50 %535626/21/2024

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
61.000.010.050.030.030.000.00 %221226/21/2024
62.000.010.150.020.08-0.03-60.00 %174436/21/2024
63.000.010.050.040.03-0.01-20.00 %63926/21/2024
64.000.020.030.030.025-0.05-62.50 %52376/21/2024
65.000.010.150.040.08-0.09-69.23 %2001756/21/2024
66.000.020.090.050.055-0.21-80.77 %992826/21/2024
67.000.070.090.070.08-0.43-86.00 %1,2232,1946/21/2024
68.000.160.230.200.195-0.73-78.49 %1762066/21/2024
69.000.360.430.390.395-1.01-72.14 %1,381616/21/2024
70.000.680.760.720.72-1.30-64.36 %8131096/21/2024
71.001.181.261.211.22-1.14-48.51 %848106/21/2024
72.001.821.922.341.87-5.21-69.01 %17206/21/2024
73.002.572.712.392.640.000.00 %9306/21/2024
74.002.813.854.453.330.000.00 %806/21/2024
75.004.255.304.504.7750.000.00 %406/21/2024
76.005.056.504.805.7750.000.00 %606/21/2024
77.005.157.500.006.3250.000.00 %00-
78.005.307.700.006.500.000.00 %00-
79.006.958.600.007.7750.000.00 %00-
80.007.359.750.008.550.000.00 %00-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

GILD Discussion

View Posts
north40000 north40000 7 days ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21โ€ฆ The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 daysโ€ฆ"
๐Ÿ‘๏ธ0
north40000 north40000 1 week ago
How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 weeks ago
There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 weeks ago
A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 weeks ago
They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 weeks ago
''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 4 weeks ago
The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 months ago
The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 3 months ago
Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
GILD new 52 week high
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 7 months ago
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 7 months ago
Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 7 months ago
The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
๐Ÿ‘๏ธ0
Greedy G Greedy G 9 months ago
~bought 9/22 $80 calls .08c
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 1 year ago
Why is an oral prodrug of Remdesivir anything to get excited about?
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
๐Ÿ‘๏ธ0
fink fink 1 year ago
Christmas sell off over, last day to lock in any paper tax loss. LOL

Whoโ€™s losing money here?

I think we start the trend back up into Q1
๐Ÿ‘๏ธ0
fink fink 2 years ago
It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

Thatโ€™s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bankโ€™s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
๐Ÿ‘๏ธ0
PennyPusher786 PennyPusher786 2 years ago
It's at a 3 year high
๐Ÿ‘๏ธ0
fung_derf fung_derf 2 years ago
Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
๐Ÿ‘๏ธ0
fink fink 2 years ago
Nice to see GILD over $80

Wonder if I should trim some? Itโ€™s been eating chit pie for some time.
Still donโ€™t see why the spike.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 years ago
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
๐Ÿ‘๏ธ0
Zeppo Zeppo 2 years ago
Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 2 years ago
GILD details why the purportedly-positive Trodelvy data from Mar 2022 werenโ€™t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a โ€œtrend in improvementโ€ means non-statsig. OS could conceivably turn statsig in a later data cut, but thatโ€™s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.
๐Ÿ‘๏ธ0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 years ago
ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 years ago
Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 years ago
Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 2 years ago
ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

PDUFA date (for 2nd line) is April 1.
๐Ÿ‘๏ธ0
mick mick 2 years ago
GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
GILD News: Jefferies Thinks Gilead Sciencesโ€™ Stock is Going to Recover 03/02/2022 03:35:55 AM
๐Ÿ‘๏ธ0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
58.39 ? 0.47 (0.81%)
Volume: 13,007,627 @03/11/22 7:41:31 PM EST
Bid Ask Day's Range
58.2 58.4 57.955 - 59.185
GILD Detailed Quote
๐Ÿ‘๏ธ0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
61.33 ? 0.22 (0.36%)
Volume: 9,751,206 @02/15/22 4:17:32 PM EST
Bid Ask Day's Range
61.15 61.33 60.97 - 61.515
GILD Detailed Quote
๐Ÿ‘๏ธ0
mick mick 2 years ago
Gilead Sciences Inc (GILD)
63.9 ? -1.49 (-2.28%)
Volume: 12,392,843 @02/04/22 7:58:42 PM EST
Bid Ask Day's Range
63.8 64.0 63.8722 - 65.61
GILD Detailed Quote
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 2 years ago
GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

The 3% royalty is a pretty big deal since Biktarvyโ€™s had annualized US sales of $8.4B(!) in 4Q21.

* ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 2 years ago
GILD 4Q21 resultsโ€ฆ

PR:
https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

CC slides:
https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b
๐Ÿ‘๏ธ0
mick mick 2 years ago
https://www.otcmarkets.com/stock/GILD
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
GILD vs BMY in LBCL CAR-Tโ€”who has the edge?

https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

Both Yescarta and Breyanzi are poised to take share from stemcell transplants.
๐Ÿ‘๏ธ0
mick mick 3 years ago
https://www.otcmarkets.com/stock/GILD
๐Ÿ‘๏ธ0
dhbuzz dhbuzz 3 years ago
GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

GLTA
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 3 years ago
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

Iโ€™m not sure why it took almost a year for this trial to begin enrolling patientsโ€”the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
๐Ÿ‘๏ธ0
Michel Michel 3 years ago
I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-as-theyre-saying


Brilacidina y Remdesivir
๐Ÿ‘๏ธ0
Ultimate01 Ultimate01 3 years ago
Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.
๐Ÿ‘๏ธ0
mick mick 3 years ago
Gilead Sciences Inc (GILD)
66.68 ? 0.21 (0.32%)
Volume: 6,519,261 @11/05/21 7:59:38 PM EDT
Bid Ask Day's Range
66.16 66.68 65.76 - 66.87
GILD Detailed Quote
๐Ÿ‘๏ธ0
mick mick 3 years ago
i think so they got ah good pipeline though
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock